OBJECTIVE: To evaluate the use of an aromatase inhibitor for the treatment of endometriosis-related chronic pelvic pain. DESIGN: Retrospective analysis. SETTING: Academic medical center outpatient reproductive endocrinology clinic. PATIENT(S): Sixteen patients with endometriosis and chronic pelvic pain who previously failed conventional medical and/or surgical therapy. INTERVENTION(S): Treatment with the aromatase inhibitor letrozole (2.5 mg/d) plus a gonadotropin suppressor (norethindrone acetate, 2.5 mg/d, or a combination oral contraceptive [OC]) for an average of 6 months. MAIN OUTCOME MEASURE(S): Pain scores were reported at each visit using a visual analogue scale from 0 to 10 (0: no pain, 10: maximum pain). RESULT(S): Sixteen patients were treated with an aromatase inhibitor for 180 ± 31 days. The median pain score at the start of therapy was 7, and at the end of therapy it was 1.5. In the nine patients who were evaluated after discontinuing therapy, pain scores returned to pretreatment levels. We did not find any correlation between the length of treatment and the overall improvement in pain score. CONCLUSION(S): Letrozole plus a gonadotropin suppressor substantially improved pain symptoms in patients with endometriosis refractory to conventional therapies; however, pain recurred after treatment was completed.
OBJECTIVE: To evaluate the use of an aromatase inhibitor for the treatment of endometriosis-related chronic pelvic pain. DESIGN: Retrospective analysis. SETTING: Academic medical center outpatient reproductive endocrinology clinic. PATIENT(S): Sixteen patients with endometriosis and chronic pelvic pain who previously failed conventional medical and/or surgical therapy. INTERVENTION(S): Treatment with the aromatase inhibitor letrozole (2.5 mg/d) plus a gonadotropin suppressor (norethindrone acetate, 2.5 mg/d, or a combination oral contraceptive [OC]) for an average of 6 months. MAIN OUTCOME MEASURE(S): Pain scores were reported at each visit using a visual analogue scale from 0 to 10 (0: no pain, 10: maximum pain). RESULT(S): Sixteen patients were treated with an aromatase inhibitor for 180 ± 31 days. The median pain score at the start of therapy was 7, and at the end of therapy it was 1.5. In the nine patients who were evaluated after discontinuing therapy, pain scores returned to pretreatment levels. We did not find any correlation between the length of treatment and the overall improvement in pain score. CONCLUSION(S): Letrozole plus a gonadotropin suppressor substantially improved pain symptoms in patients with endometriosis refractory to conventional therapies; however, pain recurred after treatment was completed.
Authors: Lisa L Amsterdam; William Gentry; Smeta Jobanputra; Michael Wolf; Stephen D Rubin; Serdar E Bulun Journal: Fertil Steril Date: 2005-08 Impact factor: 7.329
Authors: J Kitawaki; T Noguchi; T Amatsu; K Maeda; K Tsukamoto; T Yamamoto; S Fushiki; Y Osawa; H Honjo Journal: Biol Reprod Date: 1997-09 Impact factor: 4.285
Authors: Serdar E Bulun; Diana Monsavais; Mary Ellen Pavone; Matthew Dyson; Qing Xue; Erkut Attar; Hideki Tokunaga; Emily J Su Journal: Semin Reprod Med Date: 2012-01-23 Impact factor: 1.303
Authors: Yuechao Zhao; Quanxi Li; Benita S Katzenellenbogen; Lester F Lau; Robert N Taylor; Indrani C Bagchi; Milan K Bagchi Journal: Mol Endocrinol Date: 2014-12
Authors: Jason M Franasiak; Katherine A Burns; Ov Slayden; Lingwen Yuan; Marc A Fritz; Kenneth S Korach; Bruce A Lessey; Steven L Young Journal: Reprod Sci Date: 2014-07-16 Impact factor: 3.060
Authors: Soo Hyun Ahn; Stephany P Monsanto; Caragh Miller; Sukhbir S Singh; Richard Thomas; Chandrakant Tayade Journal: Biomed Res Int Date: 2015-07-12 Impact factor: 3.411